Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MOHAMMED M MILHEM

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1558429100
CMS profile
806076
Location
IOWA CITY, IA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$53.18

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $53.18 1

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $53.18 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MOHAMMED M MILHEM

NPI 1558429100 · CMS profile ID 806076

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

IOWA CITY, IA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1558429100?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MOHAMMED M MILHEM, NPI 1558429100, CMS profile ID 806076. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1558429100?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MOHAMMED M MILHEM, NPI 1558429100, CMS profile ID 806076. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1558429100?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MOHAMMED M MILHEM, NPI 1558429100, CMS profile ID 806076, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1558429100?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $53.18 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $53.1804/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242511626 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $7,538.13 7
PY2021 $18.12 2
PY2022 $21.70 2
PY2025 $53.18 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $9,472.81 4
PY2025 Principal investigator $581,246.58 77
PY2024 Principal investigator $999,952.01 109
PY2023 Recipient $1,270.00 2
PY2023 Principal investigator $827,610.63 137
PY2022 Principal investigator $1,233,503.31 110
PY2021 Principal investigator $751,345.38 31
PY2020 Principal investigator $896,218.13 99
PY2019 Recipient $476.00 1
PY2019 Principal investigator $1,105,673.41 103

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

139 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $55,638.94 12/31/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection of high-risk Stage III melanoma# A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group No dispute reported 06/30/2026 1042494535
Principal investigator 1 Merck Sharp & Dohme LLC $2,887.47 12/31/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection of high-risk Stage III melanoma# A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group No dispute reported 06/30/2026 1042494537
Principal investigator 1 Merck Sharp & Dohme LLC $3,791.21 12/31/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab No dispute reported 06/30/2026 1042498709
Principal investigator 1 Merck Sharp & Dohme LLC $188,137.09 12/31/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab No dispute reported 06/30/2026 1042498751
Principal investigator 1 Merck Sharp & Dohme LLC $6,863.29 12/31/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma# A Randomized, Double-blind Phase III Study KEYNOTE 716 No dispute reported 06/30/2026 1042501501
Principal investigator 1 Merck Sharp & Dohme LLC $24,201.24 12/31/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK 7684A Vibostolimab with Pembrolizumab Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma KEYVIBE-010 No dispute reported 06/30/2026 1042550327
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,250.00 12/22/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977083351
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,500.00 12/22/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977083357
Principal investigator 1 Immunocore Limited $2,613.68 12/21/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigators Choice in HLA-A0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma No dispute reported 06/30/2026 1051211449
Principal investigator 1 GlaxoSmithKline, LLC. $685.00 12/20/2023 Non-covered Recipient Entity
THE UNIVERSITY OF IOWA
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN AN No dispute reported 06/30/2026 1006150885
Principal investigator 1 GlaxoSmithKline, LLC. $1,150.00 12/20/2023 Non-covered Recipient Entity
THE UNIVERSITY OF IOWA
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN AN No dispute reported 06/30/2026 1006151273
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $418.95 12/08/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977083333
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $335.16 12/08/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977083339
Principal investigator 1 Merck Sharp & Dohme LLC $24,158.60 11/30/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma# A Randomized, Double-blind Phase III Study KEYNOTE 716 No dispute reported 06/30/2026 1042501493
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $750.00 11/27/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977083303
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,350.00 11/27/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977083309
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $225.00 11/27/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977083315
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,000.00 11/27/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977083321
Principal investigator 1 Genentech, Inc. $4,500.00 11/24/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Phase Ib belvarafenib alone and in combo with cobi or cobi atezo in NRAS m adv melanoma patients No dispute reported 06/30/2026 1040213843
Principal investigator 1 Deciphera Pharmaceuticals Inc. $109.00 11/13/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053726769
Principal investigator 1 Deciphera Pharmaceuticals Inc. $109.00 11/13/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053726773
Principal investigator 1 ADC Therapeutics America, Inc. $550.00 10/27/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1051208491
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15.77 10/25/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977083105
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 10/25/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977083111
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $535.50 10/25/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977083117
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $642.60 10/25/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977083123
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $900.00 10/25/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977083129
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $913.50 10/25/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977083135
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,039.50 10/25/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977083141
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,125.00 10/25/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977083147
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,285.20 10/25/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977083151
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 10/25/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977083157
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 10/25/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977083163
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 10/25/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977083169
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,086.56 10/25/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977083175
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,086.56 10/25/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977083181
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,086.56 10/25/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977083187
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,086.56 10/25/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977083193
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,086.56 10/25/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977083197
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,173.50 10/25/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977083203
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,255.40 10/25/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977083209
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,749.32 10/25/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977083215
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,749.32 10/25/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977083221
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,749.32 10/25/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977083227
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,835.00 10/25/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977083231
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,462.92 10/25/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977083237
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,462.92 10/25/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977083243
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,462.92 10/25/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977083247
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,250.00 10/25/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977083253
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.01 10/25/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977083259
Principal investigator 1 Merck Sharp & Dohme LLC $37,714.60 10/18/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab No dispute reported 06/30/2026 1042498707
Principal investigator 1 ADC Therapeutics America, Inc. $3,315.00 09/29/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1051208419
Principal investigator 1 ADC Therapeutics America, Inc. $3,328.00 09/29/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1051208423
Principal investigator 1 ADC Therapeutics America, Inc. $3,653.00 09/29/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1051208427
Principal investigator 1 ADC Therapeutics America, Inc. $3,315.00 09/29/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1051208441
Principal investigator 1 ADC Therapeutics America, Inc. $550.00 09/29/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1051208465
Principal investigator 1 ADC Therapeutics America, Inc. $550.00 09/29/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1051208467
Principal investigator 1 ADC Therapeutics America, Inc. $731.25 09/29/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1051208475
Principal investigator 1 ADC Therapeutics America, Inc. $731.25 09/29/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1051208477
Principal investigator 1 ADC Therapeutics America, Inc. $731.25 09/29/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1051208479
Principal investigator 1 ADC Therapeutics America, Inc. $1,423.50 09/29/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1051208487
Principal investigator 1 ADC Therapeutics America, Inc. $2,548.00 09/01/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1051208405
Principal investigator 1 ADC Therapeutics America, Inc. $2,749.50 09/01/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1051208407
Principal investigator 1 ADC Therapeutics America, Inc. $2,795.00 09/01/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1051208409
Principal investigator 1 ADC Therapeutics America, Inc. $2,866.50 09/01/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1051208413
Principal investigator 1 ADC Therapeutics America, Inc. $2,938.00 09/01/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1051208415
Principal investigator 1 ADC Therapeutics America, Inc. $3,328.00 09/01/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1051208421
Principal investigator 1 ADC Therapeutics America, Inc. $3,653.00 09/01/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1051208425
Principal investigator 1 ADC Therapeutics America, Inc. $731.25 09/01/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1051208469
Principal investigator 1 ADC Therapeutics America, Inc. $731.25 09/01/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1051208471
Principal investigator 1 ADC Therapeutics America, Inc. $731.25 09/01/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1051208473
Principal investigator 1 ADC Therapeutics America, Inc. $1,189.50 09/01/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1051208481
Principal investigator 1 ADC Therapeutics America, Inc. $1,189.50 09/01/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1051208483
Principal investigator 1 ADC Therapeutics America, Inc. $1,189.50 09/01/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1051208485
Principal investigator 1 ADC Therapeutics America, Inc. $1,599.00 09/01/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
ADCT-601-102 No dispute reported 06/30/2026 1051208489
Principal investigator 1 PFIZER INC. $2,116.76 08/29/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1045976143
Principal investigator 1 PFIZER INC. $5,175.30 08/29/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1046304939
Principal investigator 1 Deciphera Pharmaceuticals Inc. $545.00 08/18/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053726767
Principal investigator 1 GlaxoSmithKline, LLC. $670.00 08/09/2023 Non-covered Recipient Entity
THE UNIVERSITY OF IOWA
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN AN No dispute reported 06/30/2026 1006150895
Principal investigator 1 Genentech, Inc. $17,603.00 08/03/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Phase Ib belvarafenib alone and in combo with cobi or cobi atezo in NRAS m adv melanoma patients No dispute reported 06/30/2026 1040213787
Principal investigator 1 TRILLIUM THERAPEUTICS USA, LLC $1,650.00 08/02/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE III STUDY OF TTI621 IN COMBINATION WITH DOXORUBICIN IN PATIENTS WITH UNRESECTABLE OR METASTATIC HIGHGRADE LEIOMYOSARCOMA No dispute reported 06/30/2026 1046031857
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,350.00 07/26/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977083045
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $300.00 07/26/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977083051
Principal investigator 1 TRILLIUM THERAPEUTICS USA, LLC $18,178.25 07/26/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE III STUDY OF TTI621 IN COMBINATION WITH DOXORUBICIN IN PATIENTS WITH UNRESECTABLE OR METASTATIC HIGHGRADE LEIOMYOSARCOMA No dispute reported 06/30/2026 1046121019
Principal investigator 1 Genentech, Inc. $2,625.00 07/25/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Phase Ib belvarafenib alone and in combo with cobi or cobi atezo in NRAS m adv melanoma patients No dispute reported 06/30/2026 1040213769
Principal investigator 1 Genentech, Inc. $5,000.00 07/25/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Phase Ib belvarafenib alone and in combo with cobi or cobi atezo in NRAS m adv melanoma patients No dispute reported 06/30/2026 1040213779
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,685.49 07/10/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977083039
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,200.00 06/30/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, TWO PART OPEN-LABEL, PHASE 1B CLINICAL STUDY OF CMP-001 ADMINISTERED EITHER IN COMBINATION WITH PEMBROLIZUMAB OR AS A MONOTHERAPY IN SUBJECTS WITH ADVANCED MELANOMA No dispute reported 06/30/2026 977083023
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $510.00 06/30/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, TWO PART OPEN-LABEL, PHASE 1B CLINICAL STUDY OF CMP-001 ADMINISTERED EITHER IN COMBINATION WITH PEMBROLIZUMAB OR AS A MONOTHERAPY IN SUBJECTS WITH ADVANCED MELANOMA No dispute reported 06/30/2026 977083029
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,300.00 06/30/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, TWO PART OPEN-LABEL, PHASE 1B CLINICAL STUDY OF CMP-001 ADMINISTERED EITHER IN COMBINATION WITH PEMBROLIZUMAB OR AS A MONOTHERAPY IN SUBJECTS WITH ADVANCED MELANOMA No dispute reported 06/30/2026 977083035
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,511.62 06/23/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977083011
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,226.63 06/19/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, TWO PART OPEN-LABEL, PHASE 1B CLINICAL STUDY OF CMP-001 ADMINISTERED EITHER IN COMBINATION WITH PEMBROLIZUMAB OR AS A MONOTHERAPY IN SUBJECTS WITH ADVANCED MELANOMA No dispute reported 06/30/2026 977082973
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,850.00 06/19/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, TWO PART OPEN-LABEL, PHASE 1B CLINICAL STUDY OF CMP-001 ADMINISTERED EITHER IN COMBINATION WITH PEMBROLIZUMAB OR AS A MONOTHERAPY IN SUBJECTS WITH ADVANCED MELANOMA No dispute reported 06/30/2026 977082979
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,512.00 06/19/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, TWO PART OPEN-LABEL, PHASE 1B CLINICAL STUDY OF CMP-001 ADMINISTERED EITHER IN COMBINATION WITH PEMBROLIZUMAB OR AS A MONOTHERAPY IN SUBJECTS WITH ADVANCED MELANOMA No dispute reported 06/30/2026 977082985
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $200.00 06/19/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, TWO PART OPEN-LABEL, PHASE 1B CLINICAL STUDY OF CMP-001 ADMINISTERED EITHER IN COMBINATION WITH PEMBROLIZUMAB OR AS A MONOTHERAPY IN SUBJECTS WITH ADVANCED MELANOMA No dispute reported 06/30/2026 977082991
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $441.00 06/19/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, TWO PART OPEN-LABEL, PHASE 1B CLINICAL STUDY OF CMP-001 ADMINISTERED EITHER IN COMBINATION WITH PEMBROLIZUMAB OR AS A MONOTHERAPY IN SUBJECTS WITH ADVANCED MELANOMA No dispute reported 06/30/2026 977082997
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31,561.41 06/19/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, TWO PART OPEN-LABEL, PHASE 1B CLINICAL STUDY OF CMP-001 ADMINISTERED EITHER IN COMBINATION WITH PEMBROLIZUMAB OR AS A MONOTHERAPY IN SUBJECTS WITH ADVANCED MELANOMA No dispute reported 06/30/2026 977083005
Principal investigator 1 Genentech, Inc. $1,500.00 06/08/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Phase Ib belvarafenib alone and in combo with cobi or cobi atezo in NRAS m adv melanoma patients No dispute reported 06/30/2026 1040213721
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $286.02 06/07/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977082875
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,357.02 06/07/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977082881
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,600.00 06/07/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977082887
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,200.40 06/07/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977082893
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $107.10 06/07/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977082897
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,336.04 06/07/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977082903
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,073.20 06/07/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977082909
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,100.00 06/07/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977082913
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15,452.64 06/07/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977082919
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,839.72 06/07/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977082925
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,447.16 06/07/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977082931
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,590.80 06/07/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977082937
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,268.00 06/07/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977082943
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $918.54 06/07/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977082949
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,514.58 06/07/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977082953
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $516.60 06/07/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977082961
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $450.00 06/07/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977082967
Recipient PFIZER INC. $940.00 06/02/2023 Covered Recipient Physician MULTI PRODUCT MAPLIRPACEPT ONTORPACEPT CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1061083411
Principal investigator 1 Deciphera Pharmaceuticals Inc. $109.00 05/15/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053726765
Principal investigator 1 GlaxoSmithKline, LLC. $630.00 05/04/2023 Non-covered Recipient Entity
UNIVERSITY OF IOWA
LONG TERM FOLLOW-UP OF PARTICIPANTS EXPOSED TO GSK3377794 (NY-ESO-1C25 No dispute reported 06/30/2026 1006151253
Principal investigator 1 GlaxoSmithKline, LLC. $335.00 04/26/2023 Non-covered Recipient Entity
THE UNIVERSITY OF IOWA
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN AN No dispute reported 06/30/2026 1006150907
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,200.00 04/24/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, TWO PART OPEN-LABEL, PHASE 1B CLINICAL STUDY OF CMP-001 ADMINISTERED EITHER IN COMBINATION WITH PEMBROLIZUMAB OR AS A MONOTHERAPY IN SUBJECTS WITH ADVANCED MELANOMA No dispute reported 06/30/2026 977082799
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $693.00 04/24/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, TWO PART OPEN-LABEL, PHASE 1B CLINICAL STUDY OF CMP-001 ADMINISTERED EITHER IN COMBINATION WITH PEMBROLIZUMAB OR AS A MONOTHERAPY IN SUBJECTS WITH ADVANCED MELANOMA No dispute reported 06/30/2026 977082805
Principal investigator 1 Merck Sharp & Dohme LLC $7,136.20 04/19/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection of high-risk Stage III melanoma# A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group No dispute reported 06/30/2026 1042494539
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $7,233.78 04/06/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Dose Escalation of DF6002 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications No dispute reported 06/30/2026 1027439765
Principal investigator 1 GlaxoSmithKline, LLC. $1,005.00 03/29/2023 Non-covered Recipient Entity
THE UNIVERSITY OF IOWA
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN AN No dispute reported 06/30/2026 1006150917
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $4,112.70 03/28/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
MRD Monotherapy, combination of VSV GP w antiPD1 No dispute reported 06/30/2026 1007441191
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17,321.19 03/24/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977082735
Principal investigator 1 GlaxoSmithKline, LLC. $630.00 03/21/2023 Non-covered Recipient Entity
UNIVERSITY OF IOWA
LONG TERM FOLLOW-UP OF PARTICIPANTS EXPOSED TO GSK3377794 (NY-ESO-1C25 No dispute reported 06/30/2026 1006151283
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.00 03/13/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, TWO PART OPEN-LABEL, PHASE 1B CLINICAL STUDY OF CMP-001 ADMINISTERED EITHER IN COMBINATION WITH PEMBROLIZUMAB OR AS A MONOTHERAPY IN SUBJECTS WITH ADVANCED MELANOMA No dispute reported 06/30/2026 977082699
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,023.80 03/08/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977082693
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,966.72 03/06/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 977082687
Principal investigator 1 Immunocore Limited $19,647.73 02/16/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigators Choice in HLA-A0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma No dispute reported 06/30/2026 1051211423
Principal investigator 1 Immunocore Limited $1,000.00 02/16/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigators Choice in HLA-A0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma No dispute reported 06/30/2026 1051211443
Recipient PFIZER INC. $330.00 02/14/2023 Covered Recipient Physician ONTORPACEPT CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1046309945
Principal investigator 1 Immunocore Limited $1,500.00 02/09/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigators Choice in HLA-A0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma No dispute reported 06/30/2026 1051211417
Principal investigator 1 Immunocore Limited $6,100.00 02/09/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigators Choice in HLA-A0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma No dispute reported 06/30/2026 1051211429
Principal investigator 1 Immunocore Limited $5,750.00 02/09/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigators Choice in HLA-A0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma No dispute reported 06/30/2026 1051211437
Principal investigator 1 Genentech, Inc. $8,505.00 02/02/2023 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Phase Ib belvarafenib alone and in combo with cobi or cobi atezo in NRAS m adv melanoma patients No dispute reported 06/30/2026 1040213757
Principal investigator 1 GlaxoSmithKline, LLC. $1,005.00 01/25/2023 Non-covered Recipient Entity
THE UNIVERSITY OF IOWA
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN AN No dispute reported 06/30/2026 1006151263
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $34,956.00 01/19/2023 Non-covered Recipient Entity
University Of Iowa
MRD Monotherapy, combination of VSV GP w antiPD1 No dispute reported 06/30/2026 1022140519